AB Science (AB.PA) Announces That FDA Authorization (IND) Has Been Granted for the Initiation of Its Phase 3 Study in Severe Asthma. Patient Recruitment Commences in the US
9/14/2011 10:15:00 AM
PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (Paris:AB)(NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced today that it has obtained IND status (Investigation New Drug – authorization to administer an investigational drug to humans) from the US Food and Drug Administration (FDA) and can now commence its phase 3 study of masitinib in severe persistent asthma in the US. This study had previously received European authorization and has therefore already commenced patient recruitment from European sites earlier this year.